Cargando…

Targeting angiogenesis for liver cancer: Past, present, and future

Liver cancer, mostly hepatocellular carcinoma (HCC), is the second leading cause of cancer mortality globally. Most patients were diagnosed at an advanced stage, and systemic therapy is the standard of care. All the approved systemic therapies for HCC are molecular targeted therapies with anti-angio...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Xiao-Dong, Tang, Zhao-You, Sun, Hui-Chuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chongqing Medical University 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452391/
https://www.ncbi.nlm.nih.gov/pubmed/32884987
http://dx.doi.org/10.1016/j.gendis.2020.03.010
_version_ 1783575150364459008
author Zhu, Xiao-Dong
Tang, Zhao-You
Sun, Hui-Chuan
author_facet Zhu, Xiao-Dong
Tang, Zhao-You
Sun, Hui-Chuan
author_sort Zhu, Xiao-Dong
collection PubMed
description Liver cancer, mostly hepatocellular carcinoma (HCC), is the second leading cause of cancer mortality globally. Most patients were diagnosed at an advanced stage, and systemic therapy is the standard of care. All the approved systemic therapies for HCC are molecular targeted therapies with anti-angiogenic effects targeting the vascular endothelial growth factor signaling pathway. Sorafenib and lenvatinib are the first-line treatment, and regorafenib, ramucirumab, and cabozantinib are second-line treatment options. Although anti-PD-1 antibodies, including nivolumab and pembrolizumab, demonstrated promising anti-tumor effects as monotherapy for advanced HCC in phase II clinical trials, both failed in phase III studies. Anti-angiogenic treatment remains the backbone of systemic therapy for HCC. In this review, we summarized the approved anti-angiogenic medicines and discussed the potential strategies to improve the efficacy of anti-angiogenic therapy, including combination therapy with other treatments, and discussed the approaches to overcome the drawbacks of anti-angiogenic therapies.
format Online
Article
Text
id pubmed-7452391
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Chongqing Medical University
record_format MEDLINE/PubMed
spelling pubmed-74523912020-09-02 Targeting angiogenesis for liver cancer: Past, present, and future Zhu, Xiao-Dong Tang, Zhao-You Sun, Hui-Chuan Genes Dis Article Liver cancer, mostly hepatocellular carcinoma (HCC), is the second leading cause of cancer mortality globally. Most patients were diagnosed at an advanced stage, and systemic therapy is the standard of care. All the approved systemic therapies for HCC are molecular targeted therapies with anti-angiogenic effects targeting the vascular endothelial growth factor signaling pathway. Sorafenib and lenvatinib are the first-line treatment, and regorafenib, ramucirumab, and cabozantinib are second-line treatment options. Although anti-PD-1 antibodies, including nivolumab and pembrolizumab, demonstrated promising anti-tumor effects as monotherapy for advanced HCC in phase II clinical trials, both failed in phase III studies. Anti-angiogenic treatment remains the backbone of systemic therapy for HCC. In this review, we summarized the approved anti-angiogenic medicines and discussed the potential strategies to improve the efficacy of anti-angiogenic therapy, including combination therapy with other treatments, and discussed the approaches to overcome the drawbacks of anti-angiogenic therapies. Chongqing Medical University 2020-04-07 /pmc/articles/PMC7452391/ /pubmed/32884987 http://dx.doi.org/10.1016/j.gendis.2020.03.010 Text en © 2020 Chongqing Medical University. Production and hosting by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Zhu, Xiao-Dong
Tang, Zhao-You
Sun, Hui-Chuan
Targeting angiogenesis for liver cancer: Past, present, and future
title Targeting angiogenesis for liver cancer: Past, present, and future
title_full Targeting angiogenesis for liver cancer: Past, present, and future
title_fullStr Targeting angiogenesis for liver cancer: Past, present, and future
title_full_unstemmed Targeting angiogenesis for liver cancer: Past, present, and future
title_short Targeting angiogenesis for liver cancer: Past, present, and future
title_sort targeting angiogenesis for liver cancer: past, present, and future
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452391/
https://www.ncbi.nlm.nih.gov/pubmed/32884987
http://dx.doi.org/10.1016/j.gendis.2020.03.010
work_keys_str_mv AT zhuxiaodong targetingangiogenesisforlivercancerpastpresentandfuture
AT tangzhaoyou targetingangiogenesisforlivercancerpastpresentandfuture
AT sunhuichuan targetingangiogenesisforlivercancerpastpresentandfuture